DJI
+0.77%
SPX
+0.83%
IXIC
+1.02%
FTSE
0.00%
N225
+0.06%
AXJO
+0.08%

Fresenius Medical Care AG Launches Pilot Program for Enhanced Kidney Treatment in Mexico

publisher logo
Cashu
1 day ago
Cashu TLDR
  • Fresenius Medical Care initiates a pilot program in Mexico to expand access to High-Volume Hemodiafiltration for underserved patients.
  • The program installs 150 Fresenius Medical Care 5008S CorDiax systems, improving infrastructure and patient access to renal care.
  • Fresenius Medical Care aims to enhance treatment quality and patient outcomes while prioritizing underserved populations in healthcare.

Fresenius Medical Care Launches Pilot Program for Enhanced Kidney Treatment in Mexico

Fresenius Medical Care AG & Co. KGaA, a prominent leader in renal disease products and services, initiates an innovative pilot program in Mexico aimed at expanding access to High-Volume Hemodiafiltration (HighVolumeHDF) for underserved patients. In collaboration with the Coordination of National Institutes of Health and Specialty Hospitals (CCINSHAE), this initiative specifically targets low-income individuals lacking medical coverage, facilitating treatment at seven out of ten CCINSHAE facilities throughout the country. The program represents a significant step toward addressing the healthcare disparities faced by chronic kidney disease (CKD) patients in Mexico, who often encounter barriers to necessary medical care.

The pilot program operates under a two-year contract that includes the installation of 150 Fresenius Medical Care 5008S CorDiax systems across the designated centers. This move not only enhances the infrastructure for renal care but also provides a lifeline to patients who previously had inadequate access to either public or private healthcare options. To date, the initiative has successfully enrolled 240 new patients, in addition to 410 ongoing patients who began receiving HighVolumeHDF treatments last year. The transition to HighVolumeHDF therapy is particularly beneficial, as it is proven to improve patient outcomes and overall well-being while offering a more cost-effective solution for healthcare systems.

Edgar Robles, Managing Director of Care Enablement Commercial Operations at Fresenius Medical Care Mexico, underscores the program's dual objectives: enhancing the quality of treatment and improving patient outcomes, while streamlining operational processes for healthcare providers. With strong support from clinical research, Fresenius Medical Care remains dedicated to advancing innovative therapies such as HighVolumeHDF in various markets, including the United States. This commitment is poised to elevate the standards of dialysis care globally, ultimately enriching the quality of life for patients grappling with chronic kidney disease.

In addition to this program, Fresenius Medical Care's focus on expanding access to advanced renal therapies reflects a broader trend in the healthcare industry towards inclusivity and improved patient care. By prioritizing underserved populations, the company not only fulfills a critical need but also sets a precedent for similar initiatives in other regions facing healthcare challenges.

The pilot program in Mexico signifies a vital advancement in renal treatment accessibility, demonstrating Fresenius Medical Care's dedication to improving patient lives through innovative solutions and strategic partnerships within the healthcare ecosystem.

The content provided here is for informational purposes only and should not be considered financial or investment advice. Investing in stocks carries risks, including potential loss of principal. Always do your own research and consult with a licensed financial advisor before making any investment decisions. We are not responsible for any losses or damages resulting from your use of this information.

More News

Feature in Progress
This section is under development. Check back soon for updates!
Join our newsletter to keep up to date with us!
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

© 2024 Cashu PTY LTD.